Pricey Therapies Mean NIH Needs More Money to Keep Up: Official (1)

Promising new drug treatments are expensive, and the NIH needs more money to ensure a critical link in the research process can keep up, an FDA official said July 24.

“There needs to be funding for this type of science,” Janet Woodcock said in reference to translational science. “And it needs to be recognized as a critical scientific link in the chain.” Woodcock is director of the FDA’s Center for Drug Evaluation and Research.

Translational science means using anything found from labs, clinics, and pre-clinical trial research to specifically improve health outcomes. Scientists take those findings and translate them to ...